Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Abbott To Co-Promote AstraZeneca's Crestor | Contract Pharma

What are you searching for?

Sign in
Breaking News

Abbott To Co-Promote AstraZeneca’s Crestor

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott and AstraZeneca have entered into an agreement for Abbott to promote AZ’s cholesterol drug Crestor. Under the terms of the agreement, Abbott will obtain the non-exclusive right to promote the drug alongside AZ in the U.S., excluding Puerto Rico. Financial terms were not disclosed.
   
This agreement is the second collaboration between the two companies. In 2006, they announced an agreement to develop a fixed-dose combination of the active ingredients in Abbott’s investigational TriLipix and AZ’s Crestor, with plans to submit a NDA to FDA in 2009. An NDA for TriLipix for use as monotherapy and in combination with statins has been submitted to the FDA and is currently under review.
   
“This agreement will allow AstraZeneca to increase share of voice for Crestor among physicians whose patients may benefit from this therapy. We see this as a good fit for both companies as this agreement allows us to leverage Abbott’s established presence in the dyslipidemia space,” said Mike Tilton, vice president of Primary Care, AstraZeneca.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters